Literature DB >> 1729069

Recurrent Pseudomonas aeruginosa pneumonia in an intensive care unit.

D R Silver1, I L Cohen, P F Weinberg.   

Abstract

We reviewed the records of all patients in the intensive care unit (ICU) who had Pseudomonas aeruginosa pneumonia over a 2.5-year period. Of patients with P aeruginosa pneumonia, 20 of 34 survived the initial episode of pneumonia. Ten of these 20 developed recurrence. In the nonrecurrent group, nine of ten survived hospitalization, compared to only four of ten in the recurrent group. Comparing the recurrent to the nonrecurrent group, factors associated with recurrence were the APACHE 2 score (12.3 +/- 2.7 vs 8.6 +/- 4.2 [p less than 0.03]), APS score (7.0 +/- 3.5 vs 2.7 +/- 2.1 [p less than 0.01]), and chronic pulmonary disease (8/10 vs 2/10 [p less than 0.05]). The recurrent P aeruginosa group was younger (63 +/- 10 vs 74 +/- 11 years old [p less than 0.03]) and spent more time receiving mechanical ventilation (95 +/- 64 vs 26 +/- 36 days [p less than 0.01]), in the ICU (101 +/- 61 vs 33 +/- 35 days [p less than 0.01]), and in the hospital (144 +/- 77 vs 84 +/- 32 days [p less than 0.03]). Although not statistically significant, in the recurrent group, eight of ten patients had tracheostomy and seven of ten had COPD, vs three of ten and two of ten, respectively, in the nonrecurrent group. Recurrent P aeruginosa pneumonia in the ICU is associated with increased morbidity and mortality and does not appear to be related to the adequacy of antibiotic treatment. Chronic lung disease appears to predispose patients to recurrent P aeruginosa pneumonia.

Entities:  

Mesh:

Year:  1992        PMID: 1729069     DOI: 10.1378/chest.101.1.194

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

1.  Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion.

Authors:  Daniel Aiello; John D Williams; Helena Majgier-Baranowska; Ishan Patel; Norton P Peet; Jin Huang; Stephen Lory; Terry L Bowlin; Donald T Moir
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

Review 2.  Management of antimicrobial use in the intensive care unit.

Authors:  F Alvarez-Lerma; M Palomar; S Grau
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Pseudomonas aeruginosa phage lysate as an immunobiological agent. 1. Selection of Pseudomonas aeruginosa clinical strains for phage lysate preparation.

Authors:  G Sekaninová; M Kolárová; J Pillich; J Seménka; H Slavíková; D Kubícková; V Zajícová
Journal:  Folia Microbiol (Praha)       Date:  1999       Impact factor: 2.099

4.  Enteral glutamine supplementation reducing infectious morbidity in burns patients: a randomised controlled trial.

Authors:  Vishwanath M Pattanshetti; Rajesh S Powar; Ashok S Godhi; S C Metgud
Journal:  Indian J Surg       Date:  2009-09-02       Impact factor: 0.656

5.  Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept.

Authors:  Sara Gil-Perotin; Paula Ramirez; Veronica Marti; Jose Miguel Sahuquillo; Eva Gonzalez; Isabel Calleja; Rosario Menendez; Juan Bonastre
Journal:  Crit Care       Date:  2012-05-23       Impact factor: 9.097

6.  Recurrent Pseudomonas aeruginosa Infection in Chronic Lung Diseases: Relapse or Reinfection?

Authors:  Ho-Kee Yum; I-Nae Park; Bo-Mun Shin; Soo-Jeon Choi
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-10-31

7.  Acinetobacter baumannii infection in prior ICU bed occupants is an independent risk factor for subsequent cases of ventilator-associated pneumonia.

Authors:  Eirini Tsakiridou; Demosthenes Makris; Zoe Daniil; Efstratios Manoulakas; Vasiliki Chatzipantazi; Odysseas Vlachos; Grigorios Xidopoulos; Olympia Charalampidou; Epaminondas Zakynthinos
Journal:  Biomed Res Int       Date:  2014-07-02       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.